Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma

NCT01681212 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Ipilimumab
DRUG: Dacarbazine

Sponsor

Bristol-Myers Squibb